Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448035 | 1.00 | NAPRT (0.58) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3463758 | 0.98 | NAPRT (0.56) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2179960 | 0.85 | NAPRT (0.55) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL24963302 | 0.85 | NAPRT (0.44) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL7342181 | 0.83 | NAPRT (0.43) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2770958 | 0.83 | PARP1 (0.51) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL10427732 | 0.82 | NAPRT (0.51) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| Lithium Ion SCHEMBL3463755 | 0.81 | NAPRT (0.42) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL16967455 | 0.81 | NAPRT (0.50) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL26054706 | 0.80 | NAPRT (0.41) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | claimed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL MYERS-SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3935058-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-11219593-B2 | Yarrow fresh-plant pressed juice concentrate, production, and use | SYMRISE AG (DE) | 2022-01-11 | — | — | US | disclosed |
| EP-3564217-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2021-01-27 | — | — | EP | disclosed |
| EP-3675809-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2020-07-08 | — | — | EP | disclosed |
| US-20200188290-A1 | YARROW FRESH-PLANT PRESSED JUICE CONCENTRATE, PRODUCTION, AND USE | SYMRISE AG (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110573141-A | Concentrate of freshly squeezed plant juice of milfoil, its production and use | 西姆莱斯有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-10472333-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-11-12 | — | — | US | disclosed |
| US-10150744-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-12-11 | — | — | US | disclosed |
| US-20180319752-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-11-08 | — | — | US | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081294-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| EP-3020707-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20090156485-A1 | METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS | BASE SE (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| CN-101073781-A | 4-dimethy-pyridine organic molecular-catalyst containing dinaphthalene chiral functional based and its production | UNIV TIANJIN (CN) | 2007-11-21 | — | — | CN | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081294-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX2, P2RX1, P2RX4 | NAPRT 1513/4885KDM4E 2443/4885TDP1 3394/4885 |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | NAPRT 4191/4885KDM4E 2322/4885TDP1 1157/4885 |
| US-10472333-B2 | P2X4 receptor antagonist | P2RX2, P2RX1, P2RX3 | NAPRT 1673/4885KDM4E 2458/4885TDP1 3056/4885 |
| US-20090156485-A1 | METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS | KRT18, KRTCAP2, CUTA | NAPRT 4162/4885KDM4E 1850/4885TDP1 4744/4885 |
| US-10150744-B2 | P2X4 receptor antagonist | P2RX2, P2RX1, P2RX4 | NAPRT 1513/4885KDM4E 2443/4885TDP1 3394/4885 |
| US-20180319752-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX2, P2RX1, P2RX3 | NAPRT 1673/4885KDM4E 2458/4885TDP1 3056/4885 |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, JAK3, IFNAR1 | NAPRT 4191/4885KDM4E 2322/4885TDP1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.